Explore the latest available issue and the archive. Employer links open directly on the hiring company’s website.
Account service update
Clinical / Medtech / Careers
Roche extends Phase III follow-up for vamikibart while AnX examines documented review-time results from separate FDA submissions.
2
verified developments
5
public boards refreshed
5
current openings
Previous reports
Saturday issueVaxcyte closes $1.15 billion in offerings while Esaote, bioAffinity and NurExone define their next operating steps.
Read report
Friday issueLife Biosciences reports an early safety readout while Innovent, Alumis, Perceive Bio and TRexBio move evidence, enrollment and capital forward.
Read report
Thursday issueBio-Techne opens a cell-therapy materials facility while Viatris, ADC Therapeutics, Nuevocor and Edgewise move capital and programs into new operating phases.
Read report
Wednesday issueAlvotech and LOTTE define a Syracuse manufacturing path while four specialized programs reach funding, evidence, enrollment and portfolio decisions.
Read report
Tuesday issueRepligen closes BioLife, Spyre prices $350 million and three programs move into clinical, regulatory and manufacturing execution.
Read report
Monday issueVaxcyte clears a pivotal vaccine readout as GE HealthCare, Alector, CSL and Alvotech reshape development and manufacturing paths.
Read report
Sunday issueGenmab reports a 109-patient ADC cohort while Agenus follows a small immunotherapy cohort to three years.
Read report
Friday issueNovartis licenses an mRNA-encoded engager as Regeneron and AstraZeneca outline the evidence still to come.
Read report
Thursday issueRegeneron and Sanofi expand long-acting antibody work as Wave, ZYUS and Renew define new development questions.
Read report
Wednesday issueDyne reports longer-term DM1 data as Wave, Pharmazz and Candel move RNA, neurotrauma and oncology programs forward.
Read report
Tuesday issueAstraZeneca backs Summit's oncology combinations while Novo Nordisk and Aptadir fund new programs and Lilly sharpens an oral GLP-1 comparison.
Read report
Monday issueMirum and Kodiak report pivotal trial results as Zymeworks and OSE clarify their next operating steps.
Read report
Thursday issueLisata acquires Marea and signs a $225 million financing agreement while Thursday's active biopharma job sample rises 22.6% from last week.
Read report
Wednesday issueReckitt maps up to $600 million for U.S. R&D and manufacturing while the Wednesday hiring sample rises 10.7% from last week.
Read report
Tuesday issueSionna cuts 46% of its workforce while 703 active biopharma opportunities added before cutoff are 82.1% above last Tuesday.
Read report
Monday issueEnhertu improves progression-free survival while 131 active biopharma opportunities added before cutoff are 89.9% above last Monday.
Read report
Sunday issueRoche reports a Tam-Peli survival benefit while 494 active biopharma opportunities added before cutoff are 75.2% above last Sunday.
Read report
Saturday issueSystImmune selects an iza-bren Phase 3 dose while 485 active biopharma opportunities added before cutoff are 86.5% above last Saturday.
Read report
Friday issueImmutep resets efti development and manufacturing while 772 active biopharma opportunities added before cutoff are 24.3% above last Friday.
Read report
Thursday issueLonza plans a commercial spray-drying facility in Bend with more than 80 initial jobs; 818 active biopharma opportunities added before cutoff are 42.3% above last Thursday.
Read report
Wednesday issueGilead opens a 182,000-square-foot Foster City research center; 887 active biopharma opportunities added before cutoff put Wednesday volume 24.1% above last week.
Read report
Tuesday issueSandoz plans a $300 million biosimilar facility while 440 active biopharma opportunities added before cutoff trail last Tuesday by 19.7%.
Read report
Monday issueNovo Nordisk reports first STEP Young Phase 3 results while 81 active biopharma opportunities added before cutoff lift Monday volume 52.8%.
Read report
Sunday issuePulmovant schedules Phase 2 PHocus topline results for September 8 while 406 active biopharma opportunities added before cutoff lift Sunday volume 78.9%.
Read report
Saturday issueNovartis reports a Phase III miss while an FDA-approved therapy-and-diagnostic pathway and 312 newly added opportunities keep execution broad.
Read report
Friday issueCuria opens a $200 million fill-finish expansion while 770 active biopharma opportunities added before cutoff remain near last Friday.
Read report
Thursday issueUltragenyx plans an expense review after Aspire misses while 742 active biopharma opportunities added before cutoff lift Thursday volume 60.3%.
Read report
Wednesday issueTScan cuts about 75% of its workforce while 901 active biopharma opportunities added before cutoff lift Wednesday volume 67.2%.
Read report
Tuesday issueAlumis reports a mixed lupus readout while 730 active biopharma opportunities added before cutoff lift Tuesday volume 40.1%.
Read report
Monday issuePalvella completes an NDA submission while 75 active biopharma opportunities added before cutoff lift Monday volume 25%.
Read report
Sunday issueCytokinetics leads three ESC evidence updates while 344 active biopharma opportunities added before cutoff lift Sunday volume 21.1%.
Read report
Saturday issueTrinity Biotech's operating-model shift leads four developments while 316 active biopharma opportunities added before cutoff lift Saturday volume 47%.
Read report
Friday issueEvonik's planned Vancouver GMP expansion leads five developments while 953 active biopharma opportunities added before cutoff widen the execution signal.
Read report
Thursday issueRevolution Medicines' first broad RAS approval leads five developments while 696 active biopharma opportunities added before cutoff show broad execution demand.
Read report
Wednesday issueElanco's completed Kansas expansion leads five developments while 768 active biopharma opportunities added before cutoff show broad specialized demand.
Read report
Tuesday issueCambrex's inspection milestone leads five developments while 684 active biopharma opportunities added before cutoff show broad execution demand.
Read report
Monday issueRoche's newly cleared pTau217 assay leads five developments while 88 active biopharma roles added before cutoff keep the execution signal broad.
Read report
Sunday issueOrum's FDA clearance leads a quiet Sunday news cycle while 377 active biopharma opportunities added before cutoff show broad execution demand.
Read report
Saturday issueIovance's completed hiring signal leads a quieter news window, alongside tools-sector continuity, a small clinical-stage financing, and broad Saturday hiring.
Read report
Friday issueScholar Rock's fill-finish pivot leads a day of milestone-linked capital, an Alzheimer's blood-test clearance, transplant evidence, and hiring.
Read report
Thursday issueAmylyx's upsized offering leads a day of concrete execution signals in synthesis capacity, antibody discovery, vaccine CMC, and hiring.
Read report
Wednesday issueA North Carolina manufacturing milestone leads a day that also brought pivotal oncology data, a new AI-biotech launch, and a clinical-stage licensing move.
Read report
Tuesday issueNew analytical capacity, manufacturing investment, pipeline progress, and post-deal restructuring are reshaping where biotech opportunities appear.
Read report
Monday issueClinical setbacks and acquisition-driven cuts shape the day, while biotech and biopharma employers continue recruiting in statistics, regulatory, manufacturing, quality, and cell therapy.
Read report
Sunday issueThe Sunday biotech job market was quieter, not stalled, with continued demand across clinical operations, laboratory systems, manufacturing, and digital health.
Read reportUnderstand
Concise biotech reporting connects clinical, regulatory, and workforce developments.
Focus
Biotech hiring signals highlight the functions, employers, and locations worth watching.
Act
Follow direct employer links and check the current requirements and availability.